• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    6/6/23 1:31:29 PM ET
    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ALVR alert in real time by email

    Gainers

    • Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 66.5% to $3.13 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 88.5 million, which is 38144.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.3 million.
    • Synlogic (NASDAQ:SYBX) stock rose 25.39% to $0.61. As of 13:30 EST, Synlogic's stock is trading at a volume of 413.1K, which is 135.4% of its average full-day volume over the last 100 days. The company's market cap stands at $41.6 million.
    • Castle Biosciences (NASDAQ:CSTL) shares moved upwards by 23.62% to $14.41. Castle Biosciences's stock is trading at a volume of 3.1 million shares as of 13:30 EST. This is 1102.0% of its average full-day volume over the last 100 days. The company's market cap stands at $384.7 million.
    • Tenon Medical (NASDAQ:TNON) stock moved upwards by 22.54% to $1.25. Tenon Medical's stock is trading at a volume of 80.2K shares as of 13:30 EST. This is 226.2% of its average full-day volume over the last 100 days. The company's market cap stands at $14.0 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) shares rose 19.8% to $1.21. eFFECTOR Therapeutics's stock is trading at a volume of 2.2 million shares as of 13:30 EST. This is 173.1% of its average full-day volume over the last 100 days. The company's market cap stands at $56.9 million.
    • AlloVir (NASDAQ:ALVR) shares increased by 18.16% to $5.27. Trading volume for this security as of 13:30 EST is 289.5K, which is 120.8% of its average full-day volume over the last 100 days. The company's market cap stands at $493.2 million.

    Losers

    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock fell 45.8% to $0.91 during Tuesday's regular session. HTG Molecular Diagnostics's stock is trading at a volume of 751.0K shares as of 13:30 EST. This is 394.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.0 million.
    • NovoCure (NASDAQ:NVCR) stock decreased by 35.53% to $53.2. The current volume of 6.0 million shares is 840.5% of NovoCure's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $5.6 billion.
    • VistaGen Therapeutics (NASDAQ:VTGN) stock declined by 23.96% to $0.1. Trading volume for this security as of 13:30 EST is 9.7 million, which is 236.6% of its average full-day volume over the last 100 days. The company's market cap stands at $22.3 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock fell 23.08% to $0.5. Trading volume for this security as of 13:30 EST is 1.3 million, which is 590.0% of its average full-day volume over the last 100 days. The company's market cap stands at $35.2 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 17.25% to $3.31. As of 13:30 EST, TransCode Therapeutics's stock is trading at a volume of 102.5K, which is 220.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.8 million.
    • Myomo (AMEX:MYO) shares decreased by 16.82% to $0.47. The current volume of 452.1K shares is 90.0% of Myomo's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $9.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVR
    $CSTL
    $EFTR
    $HOTH

    CompanyDatePrice TargetRatingAnalyst
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    NovoCure Limited
    $NVCR
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    NovoCure Limited
    $NVCR
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    SEC Filings

    View All

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    3/18/26 4:45:49 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Tenon Medical Inc.

    D - Tenon Medical, Inc. (0001560293) (Filer)

    3/17/26 9:25:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    3/16/26 4:10:38 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Getz Heather C bought $50,960 worth of shares (70,000 units at $0.73), increasing direct ownership by 168% to 111,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/12/26 5:18:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

    Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA).FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product. This communication is deemed preliminary until final supervisory review.NRx continues to anticipate an FDA GDUFA decision on its ANDA application in Summer 2026 as previously announced.The ANDA process is focused on offering a preservative-free alternative in the existing ketamine market through the FDA Office of Generic Drugs and is separate from NRx's path to a New Drug Application to use ketamine in the

    3/17/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

    NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research.Minutes are consistent with previously announced oral guidance outlining a path to New Drug Approval of NRX-100 for a broadened indication of treating depression, including patients with suicidality.FDA confirmed willingness to review existing Adequate and Well Controlled Clinical Trial data as Substantial Evidence of Efficacy together with Real World Evidence from Osmind, Inc. as confirmatory evidence of efficacy.No additional clinical trials were requested.Company intends to sumbit its New D

    3/16/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J sold $792,410 worth of shares (30,779 units at $25.75), decreasing direct ownership by 43% to 40,779 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    3/17/26 4:36:05 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by William Blair

    William Blair downgraded VistaGen from Outperform to Mkt Perform

    12/17/25 11:34:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

    SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

    11/14/24 5:05:41 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

    SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

    11/14/24 4:40:57 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ALVR
    $CSTL
    $EFTR
    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care